Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.

Saved in:
Bibliographic Details
Title: Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
Authors: Fletcher K; Vanderbilt University School of Medicine, Nashville, USA. Electronic address: kylie.a.fletcher@vanderbilt.edu., Cortellini A; Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo 200, 00128, Roma, Italy; Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom., Ganta T; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kankaria R; Vanderbilt University School of Medicine, Nashville, USA., Song H; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Ye F; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Irlmeier R; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Debnath N; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Saeed A; Division of Hematology & Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Radford M; University of Iowa Healthcare, Iowa City, IA, USA., Alahmadi A; Case Western Reserve University, Division of Hematology & Oncology, Cleveland, OH, USA; Ohio State University, The James Comprehensive Cancer Center, Columbus., Diamond A; Case Western Reserve University, Division of Hematology & Oncology, Cleveland, OH, USA; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Hoimes C; Case Western Reserve University, Division of Hematology & Oncology, Cleveland, OH, USA; Duke Cancer Institute, Duke University, Durham, NC, USA., Presley CJ; Ohio State University, The James Comprehensive Cancer Center, Columbus., Owen DH; Ohio State University, The James Comprehensive Cancer Center, Columbus., Abou Alaiwi S; Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA., Nassar AH; Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA., Lamberti G; Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy., Perrone F; Medical Oncology Unit, University Hospital of Parma and Medicine and Surgery Department, University of Parma, Parma, Italy., Buti S; Medical Oncology Unit, University Hospital of Parma and Medicine and Surgery Department, University of Parma, Parma, Italy., Giusti R; Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant'Andrea, Rome, Italy., Filetti M; Phase 1 Unit, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy., Vanella V; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Mallardo D; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Sussman TA; Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA., Galetta D; IRCCS Istituto Tumori Giovanni Paolo II, Medical Thoracic Oncology Unit, Bari, Italy., Kalofonou F; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Daniels E; Department of Surgery and Cancer, Imperial College London, London, United Kingdom., Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Pinato DJ; Department of Surgery and Cancer, Imperial College London, London, United Kingdom; Department of Translational Medicine, University of Piemonte Orientale 'A. Avogadro', Novara, Italy., Nebhan C; Intermountain Health, Murray UT, USA., Berg S; Dana-Farber Cancer Institute, Boston, MA, USA., Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA., Marron TU; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Wang Y; The University of Texas MD Anderson Cancer Center, Houston., Naqash AR; Medical Oncology/TSET Phase 1 Program, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, USA., Johnson DB; Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address: douglas.b.johnson@vumc.org.
Source: Cancer letters [Cancer Lett] 2024 Aug 01; Vol. 596, pp. 217001. Date of Electronic Publication: 2024 Jun 03.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1872-7980
DOI:10.1016/j.canlet.2024.217001